AbGenomics seeks partner for psoriasis candidate handed back by Boehringer
This article was originally published in Scrip
Executive Summary
California-based AbGenomics is looking for a new partner for its humanised monoclonal antibody against CD-162, AbGn-168H, which was in development for the treatment of psoriasis and other immunological diseases under a collaboration with Boehringer Ingelheim.